Terminated PHASE4 NCT01557842

Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators

Sponsor: Biosense Webster, Inc.

Conditions Ischemic Ventricular Tachycardia

Interventions Catheter Ablation Drug Treatment

Updated 7 times since 2017 Last updated: May 13, 2017 Started: Jun 1, 2012 Primary completion: Mar 19, 2014 Completion: Mar 19, 2014

Listed as NCT01557842, this PHASE4 trial focuses on Ischemic and Ventricular Tachycardia and remains terminated or withdrawn. Sponsored by Biosense Webster, Inc., it has been updated 7 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Jul 2017 [monthly]

Terminated PHASE4

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biosense Webster, Inc.

Data source: Biosense Webster, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Austin, United States , Baltimore, United States , Boston, United States , Cleveland, United States , Columbus, United States , Lexington, United States , Los Angeles, United States , Maywood, United States and 7 more locations